Stock Events

Stock Events

TME Pharma N.V 

€0.124000
29
-€0.02-11.3%Friday 16:35

Statistics

Day High
0.14
Day Low
0.1212
52W High
0.1746
52W Low
0.049
Volume
3,117,937
Avg. Volume
2,869,698
Mkt Cap
11.68M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Oct 24Expected
Q3 2020
Q1 2021
Q3 2021
Q1 2022
Q3 2022
Q1 2024
Q3 2024
-1,146.92
-764.61
-382.31
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-3.29MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALTME.PA. It's not an investment recommendation.
TotalEnergies
5
TTE.PA
Lvmh Moet Hennessy Louis Vuitton
4
MC.PA
Axa
4
CS.PA
Engie
3
ENGI.PA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap368.89B
Merck & Co., Inc. is a global healthcare company that develops medications and vaccines for many of the same diseases TME Pharma targets, making them direct competitors in the pharmaceutical market.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. is a multinational pharmaceutical corporation that competes with TME Pharma in the development and marketing of drugs and vaccines for various diseases, including those in oncology.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol-Myers Squibb Company is a global biopharmaceutical company with a strong focus on discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases, overlapping with TME Pharma's focus areas.
Novartis
NVS
Mkt Cap303.67B
Novartis AG is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide, including areas where TME Pharma operates.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Roche's pharmaceutical division competes with TME Pharma in the oncology and inflammatory disease market.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline plc is a British multinational pharmaceutical company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products, competing in similar therapeutic areas as TME Pharma.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie Inc. is an American publicly traded biopharmaceutical company that develops and markets drugs in areas such as immunology, oncology, which are key areas of focus for TME Pharma.
AMGEN
AMGN
Mkt Cap251.94B
Amgen Inc. is an American multinational biopharmaceutical company that focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise, competing directly in the biopharmaceutical space with TME Pharma.
Sanofi
SNY
Mkt Cap106.24B
Sanofi is a global healthcare leader that discovers, develops, and distributes therapeutic solutions focused on patients' needs, including areas like immunology and oncology, where TME Pharma is active.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson is a global healthcare company that develops and sells pharmaceuticals, medical devices, and consumer health products, competing across a broad range of therapeutic areas with TME Pharma.

About

TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.
Show More
CEO
Diede van den Ouden
Employees
12
Country
Germany
ISIN
NL0015000YE1
WKN
000A3DMC3

Listings

PA
FR
ALTME.PA
F
DE
0N6A.F
STU
DE
0N6A.STU
STU
DE
0N6.STU

0 Comments

Share your thoughts

FAQs

What is TME Pharma N.V stock price today?▼
The current price of ALTME.PA is €0.12 EUR — it has decreased by -11.3% in the past 24 hours. Watch TME Pharma N.V stock price performance more closely on the chart.
What is TME Pharma N.V stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Euronext Paris exchange TME Pharma N.V stocks are traded under the ticker ALTME.PA.
Is TME Pharma N.V stock price growing?▼
ALTME.PA stock has risen by +6.53% compared to the previous week, the month change is a +20.39% rise, over the last year TME Pharma N.V has showed a +26.53% increase.
What is TME Pharma N.V market cap?▼
Today TME Pharma N.V has the market capitalization of 11.68M
What is TME Pharma N.V revenue for the last year?▼
TME Pharma N.V revenue for the last year amounts to 0 EUR.
What is TME Pharma N.V net income for the last year?▼
ALTME.PA net income for the last year is -3.29M EUR.
How many employees does TME Pharma N.V have?▼
As of November 2, 2026, the company has 12 employees.
In which sector is TME Pharma N.V located?▼
TME Pharma N.V operates in the Health & Wellness sector.
When did TME Pharma N.V complete a stock split?▼
The last stock split for TME Pharma N.V was on July 28, 2022 with a ratio of 1:100.
Where is TME Pharma N.V headquartered?▼
TME Pharma N.V is headquartered in Berlin, Germany.